整合了遗传和临床预后因素，用于评估侵袭性成人T细胞白血病/淋巴瘤的预后。
Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma.
发表日期：2023 Feb 16
作者：
Takuro Kameda, Keisuke Kataoka, Ayako Kamiunten, Michihiro Hidaka, Hiroaki Miyoshi, Nobuaki Nakano, Kisato Nosaka, Makoto Yoshimitsu, Jun-Ichirou Yasunaga, Yasunori Kogure, Kotaro Shide, Masaharu Miyahara, Takashi Sakamoto, Keiichi Akizuki, Tomonori Hidaka, Yoko Kubuki, Junji Koya, Noriaki Kawano, Kiyoshi Yamashita, Hiroshi Kawano, Takanori Toyama, Kouichi Maeda, Kosuke Marutsuka, Yoshitaka Imaizumi, Koji Kato, Takeshi Sugio, Masahito Tokunaga, Yukie Tashiro, Akifumi Takaori-Kondo, Yasushi Miyazaki, Koichi Akashi, Kenji Ishitsuka, Masao Matsuoka, Koichi Ohshima, Toshiki Watanabe, Akira Kitanaka, Atae Utsunomiya, Seishi Ogawa, Kazuya Shimoda
来源：
HAEMATOLOGICA
摘要：
侵袭性成人T细胞白血病/淋巴瘤（ATL）的预后较差，异基因造血干细胞移植（allo-HSCT）是一种治疗方法。为了鉴定经过强化化疗后预后良好的患者，这些患者不需要直接进行allo-HSCT，我们旨在改善年龄较大的侵袭性ATL患者的危险分层。
The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is a curative treatment. To identify favorable prognostic patients after intensive chemotherapy, and who therefore might not require upfront allo-HSCT, we aimed to improve risk stratification of aggressive ATL patients aged.